Dr Reddys Laboratories Share Price | Dr Reddys Laboratories Stock Screener
DRREDDY
Pharmaceuticals
Share Price NSE
₹1151.70
▼
-14.60 (-1.25%)
Share Price BSE
₹1152.60
▼
-13.90 (-1.19%)
As of July 24, 2026, the Dr Reddys Laboratories share price (NSE: DRREDDY) is ₹1,151.70 on NSE and ₹1,152.60 on BSE, down 1.25% from the previous close, with shares trading between ₹1,131.40 and ₹1,166.30, and a 52-week range of ₹1,151.70–₹1,375.70.
Analyse DRREDDY stock price history and track historical price performance.
Use the Dr Reddys Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Dr Reddys Laboratories Market Cap
₹98,724.66 Cr.
DRREDDY P/E Ratio (TTM)
24.22
Dr Reddys Laboratories P/B Ratio
2.65
EPS (TTM)
₹50.41
Dividend Yield
0.66%
Debt to Equity
0.17
DRREDDY 52 Week High
₹1375.70
Dr Reddys Laboratories 52 Week Low
₹1151.70
Operating Margin
5.00%
Profit Margin
2.76%
DRREDDY Revenue (TTM)
₹7,996.00
EBITDA
₹832.00
Net Income
₹221.00
Total Assets
₹58,123.00
Total Equity
₹38,231.00
Dr Reddys Laboratories Share Price Chart
Screen Dr Reddys Laboratories share price with an interactive chart. Analyse DRREDDY price trends and volatility across different timeframes.
Dr Reddys Laboratories Company Profile - Fundamental Screener
Screen Dr Reddys Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for DRREDDY shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE089A01031
Dr Reddys Laboratories Balance Sheet Screener
Screen DRREDDY balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 58,123 | 49,427 | 38,864 | 32,285 | 29,747 | 26,617 | 23,225 | 22,466 | 22,544 | 21,817 |
| Current Assets | 30,179 | 25,018 | 24,805 | 20,426 | 17,782 | 14,550 | 12,599 | 11,110 | 10,498 | 9,684 |
| Fixed Assets | 22,063 | 18,226 | 10,426 | 9,219 | 8,122 | 8,206 | 6,850 | 7,191 | 6,968 | 6,931 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3,145 | 2,465 | 1,021 | 427 | 769 | 871 | 412 | 2,545 | 3,079 | 1,135 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 38,231 | 33,927 | 28,255 | 23,286 | 19,212 | 17,642 | 15,599 | 14,024 | 12,572 | 12,262 |
| Share Capital | 84 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 |
| Reserves & Surplus | 37,990 | 33,466 | 28,171 | 23,330 | 19,289 | 17,755 | 15,616 | 13,994 | 12,489 | 12,179 |
Dr Reddys Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Dr Reddys Laboratories income statement and profit fundamentals.
Analyze DRREDDY quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Dr Reddys Laboratories share price evaluation.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,996 | 8,426 | 9,034 | 8,836 | 9,135 | 8,998 | 7,284 | 7,866 | 8,330 | 8,513 | 6,443 | 6,917 | 7,199 | 7,434 | 5,569 |
| Expenses | 7,164 | 7,240 | 6,531 | 6,399 | 6,818 | 6,866 | 5,283 | 5,566 | 5,962 | 6,108 | 4,781 | 4,696 | 4,894 | 5,214 | 5,024 |
| EBITDA | 832 | 1,186 | 2,503 | 2,437 | 2,317 | 2,132 | 2,001 | 2,300 | 2,368 | 2,405 | 1,662 | 2,221 | 2,305 | 2,220 | 545 |
| Operating Profit % | 5.00% | 10.00% | 23.00% | 25.00% | 23.00% | 21.00% | 25.00% | 27.00% | 26.00% | 27.00% | 24.00% | 30.00% | 29.00% | 28.00% | 8.00% |
| Depreciation | 557 | 537 | 455 | 476 | 505 | 521 | 368 | 381 | 397 | 471 | 316 | 353 | 376 | 374 | 293 |
| Interest | 106 | 126 | 66 | 83 | 91 | 94 | 59 | 60 | 76 | 82 | 35 | 37 | 35 | 39 | 32 |
| Profit Before Tax | 200 | 553 | 2,005 | 1,905 | 1,745 | 1,543 | 1,605 | 1,883 | 1,917 | 1,874 | 1,329 | 1,850 | 1,917 | 1,829 | 259 |
| Tax | -22 | 118 | 419 | 495 | 408 | 354 | 295 | 490 | 576 | 470 | 369 | 445 | 435 | 448 | 162 |
| Net Profit | 221 | 436 | 1,587 | 1,410 | 1,337 | 1,190 | 1,310 | 1,392 | 1,342 | 1,404 | 960 | 1,405 | 1,482 | 1,381 | 97 |
| EPS | 2.65 | 5.33 | 19.12 | 17.04 | 16.18 | 14.53 | 78.66 | 83.61 | 75.40 | 16.97 | 57.79 | 84.55 | 89.09 | 82.94 | 5.84 |
Dr Reddys Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen DRREDDY cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 5,674 | 4,643 | 4,543 | 5,888 | 2,811 | 3,570 | 2,984 | 2,870 | 1,803 | 2,144 |
| Investing Activities | -6,425 | -5,785 | -4,034 | -4,109 | -2,565 | -2,255 | -495 | -769 | -1,483 | -1,890 |
| Financing Activities | 829 | 1,891 | -376 | -2,686 | -242 | -30 | -2,516 | -2,133 | -444 | -369 |
| Net Cash Flow | 78 | 749 | 133 | -907 | 3 | 1,286 | -27 | -31 | -124 | -114 |
Dr Reddys Laboratories Shareholding Pattern Screener
See Dr Reddys Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Dr Reddys Laboratories promoter holding and ownership changes for DRREDDY on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 26.63% | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.65% |
| FII Holding | 33.08% | 33.20% | 35.52% | 36.36% | 37.29% | 40.08% | 41.75% | 42.27% |
| DII Holding | 30.72% | 30.44% | 27.98% | 26.74% | 25.62% | 22.90% | 21.48% | 20.73% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 7.57% | 7.65% | 7.56% | 8.04% | 8.20% | 8.07% | 8.07% | 8.07% |
| Other Holding | 1.99% | 2.07% | 2.30% | 2.22% | 2.25% | 2.30% | 2.06% | 2.29% |
| Shareholder Count | 449,665 | 455,243 | 449,216 | 451,929 | 459,605 | 403,669 | 310,403 | 267,694 |
Dr Reddys Laboratories Share Dividend Screener - Share Yield Analysis
Check Dr Reddys Laboratories dividend history with payout and yield data.
View Dr Reddys Laboratories dividend details including ex-dates and amounts for DRREDDY stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹8.00 | 0.66% |
| 2025-March | ₹8.00 | 0.64% |
| 2024-March | ₹40.00 | 3.50% |
| 2023-March | ₹40.00 | 3.25% |
| 2022-March | ₹30.00 | 3.24% |
| 2021-March | ₹25.00 | 2.91% |
| 2020-March | ₹25.00 | 2.77% |
| 2019-March | ₹20.00 | 3.20% |
| 2018-March | ₹20.00 | 3.60% |
| 2017-March | ₹20.00 | 4.81% |
Dr Reddys Laboratories Stock Index Membership
See which indices include Dr Reddys Laboratories stock.
Check DRREDDY index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE100
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEDSI
BSE INDEX BSELVI
BSE INDEX DOL100
BSE INDEX ESG100
BSE INDEX LCTMCI
BSE INDEX LMI250
BSE INDEX LRGCAP
BSE INDEX MFG
BSE INDEX SNSX50
BSE SENSEX SIXTY
BSE SENSEX SIXTY 65:35
GIFT NIFTY
INDIA VIX
NIFTY 100
NIFTY 200
NIFTY 50
NIFTY 500
NIFTY ALPHA QUALITY LOW-VOLATILITY 30
NIFTY ALPHA QUALITY VALUE LOW VOLATILITY 30
NIFTY ALPHALOWVOL
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY LOW VOLATILITY 50
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY QUALITY LOW VOLATILITY 30
NIFTY SHARIAH 25
NIFTY TOTAL MKT
NIFTY100 ENHANCED ESG
NIFTY100 EQL WGT
NIFTY100 ESG
NIFTY100 LOWVOL30
NIFTY100 QUALTY30
NIFTY50 EQL WGT
NIFTY50 SHARIAH
NIFTY50 VALUE 20
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
SENSEX NEXT 30
Dr Reddys Laboratories Market Events Screener - Corporate Actions
Get Dr Reddys Laboratories corporate actions including splits, bonuses, and buybacks.
Check Dr Reddys Laboratories stock events that may affect DRREDDY share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-23 | 2026-07-23 | Annual General Meeting | NA | -5.76% |
| 2026-07-22 | 2026-07-22 | Quarterly Result Announcement | NA | -5.16% |
| 2026-07-10 | 2026-07-10 | Dividend | ₹ 8.00 /share | -0.80% |
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | -1.48% |
| 2026-01-21 | 2026-01-21 | Quarterly Result Announcement | NA | -9.12% |
| 2025-10-24 | 2025-10-24 | Quarterly Result Announcement | NA | -3.20% |
| 2025-07-24 | 2025-07-24 | Annual General Meeting | NA | 8.66% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | -6.42% |
| 2025-07-10 | 2025-07-10 | Dividend | ₹ 8.00 /share | 10.57% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | -3.30% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -3.53% |
| 2024-11-05 | 2024-11-05 | Quarterly Result Announcement | NA | -3.20% |
| 2024-10-28 | 2024-07-27 | Split | 1:5 | 0.00% |
| 2024-07-29 | 2024-07-29 | Annual General Meeting | NA | 9.51% |
| 2024-07-16 | 2024-07-17 | Dividend | ₹ 40.00 /share | 5.60% |
Dr Reddys Laboratories Competitors Screener - Peer Comparison
Screen DRREDDY competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 466,191 | 40.90 | 61,674 | 12.69% | 11,565 | 61.52 |
| Divis Laboratories | 196,088 | 75.78 | 11,067 | 13.95% | 2,568 | 73.60 |
| Torrent Pharmaceuticals | 191,454 | 79.75 | 13,886 | 20.34% | 2,138 | 66.10 |
| Cipla | 114,318 | 29.97 | 29,045 | 2.24% | 3,870 | 47.02 |
| Zydus Life Science | 113,332 | 22.27 | 27,658 | 17.64% | 5,026 | 51.92 |
| Lupin | 110,051 | 21.47 | 29,039 | 26.75% | 5,356 | 47.81 |
| Mankind Pharma | 105,095 | 54.93 | 14,636 | 14.85% | 1,938 | 55.85 |
| Dr Reddys Laboratories | 98,725 | 24.22 | 35,059 | 3.90% | 4,158 | 29.50 |
| Aurobindo Pharma | 88,240 | 26.21 | 33,385 | 3.21% | 3,376 | 49.50 |
| Laurus Labs | 85,179 | 96.66 | 6,868 | 22.01% | 890 | 64.23 |
Dr Reddys Laboratories Company Announcements - News Screener
Screen DRREDDY latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Investor Presentation | - | |
| Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 | - | |
| Announcement under Regulation 30 (LODR)-Change in Management | - | |
| Unaudited Financial Results For The Quarter Ended June 30 2026 | - | |
| Board Meeting Outcome for Outcome Of Board Meeting | - | |
| 2026-07-18 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015- Conference Call Transcript | - |
| 2026-07-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-07-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-07-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-09 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 | - |
| 2026-07-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-06-30 | Letter To Shareholders In Relation To Integrated Annual Report Of The Company For FY 2025-26 | - |
| 2026-06-30 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-06-30 | Notice Of The 42Nd Annual General Meeting Scheduled On July 23 2026. | - |
| 2026-06-30 | Reg. 34 (1) Annual Report. | - |
| 2026-06-25 | Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 | - |
| 2026-06-22 | Closure of Trading Window | - |
| 2026-06-22 | Board Meeting Intimation for Considering The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending On June 30 2026 | - |